CanSino Biologics Inc.

About CanSino Biologics Inc.

CanSinoBIO is an industry-leading biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research, development, manufacturing, and commercialization of vaccine products for human use. Their mission is to provide innovative, high-quality, and affordable vaccines for a safer world.

Products & Services

Menhycia(r):A marketed vaccine product.

iPneucia(r) (PCV13i):A 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine recently launched domestically.

Specialties

Vaccine research and development Prevention and treatment of infectious diseases Innovative vaccine technologies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 17000000 MR: - FA: exceeding US$17 million FAN: 17000000	D: 2024-10-09 FD: 2024-10-09	1 investors

Grant Latest

2024-10-09

$17.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

X

Xuefeng Yu

Chairman and Chief Executive Officer

S

Shoubai Chao

Chief Operating Officer and Executive Director

T

Tao Zhu

Chief Scientific Officer

J

Jeanne Wang

Chief Commercial Officer and Executive Director

G

George Siber

Co-Chair

L

Luis Barreto

President of Dr. Luis Barreto & Associates

View 6 more team members with Pro

Unlock Full Team Directory

Recent News